CHELSEA CLEMENS: Open Payments
NPI 1104300987 · STAMFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,792 in 87 payments from 14 companies in 2025. Trend: 2023 $3,302 · 2024 $2,337 · 2025 $1,792
Food & beverage: $1,792
| Company | Payments | Amount |
|---|---|---|
| CSL Behring | 14 | $295 |
| AstraZeneca Pharmaceuticals LP | 10 | $202 |
| GENZYME CORPORATION | 10 | $199 |
| Novartis Pharmaceuticals Corporation | 9 | $190 |
| Regeneron Healthcare Solutions, Inc. | 9 | $173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $160 |
| Genentech USA, Inc. | 7 | $150 |
| Amgen Inc. | 4 | $96 |
| GlaxoSmithKline, LLC. | 5 | $89 |
| ABBVIE INC. | 3 | $76 |
Products named: DUPIXENT, Xolair, Andembry, TEZSPIRE, FASENRA, HYQVIA, Haegarda, NUCALA.
Industry payments across CT — which companies pay providers there.
